{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:03:23Z","timestamp":1780041803686,"version":"3.53.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106617","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:41:09Z","timestamp":1752712869000},"page":"106617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world change in annualized relapse rate and healthcare resource utilization following initiation of ofatumumab in people with multiple sclerosis"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-5425","authenticated-orcid":false,"given":"Ming-Hui","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Taiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Vekeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Ionescu-Ittu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2025.106617_bib0001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","article-title":"Mechanisms underlying progression in multiple sclerosis","volume":"33","author":"Absinta","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106617_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13696998.2020.1857257","article-title":"Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database","volume":"24","author":"Berkovich","year":"2021","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2025.106617_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106617_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103021","article-title":"Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population","volume":"53","author":"Coban","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106617_bib0005","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40120-023-00523-3","article-title":"Real-world clinical and economic outcomes among persons with multiple sclerosis initiating first- versus second- or later-line treatment with ocrelizumab","volume":"12","author":"Geiger","year":"2023","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.msard.2025.106617_bib0006","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11\u201312","key":"10.1016\/j.msard.2025.106617_bib0007","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106617_bib0008","author":"Hersh","year":"2022"},{"issue":"16 Suppl","key":"10.1016\/j.msard.2025.106617_bib0010","article-title":"Development of an algorithm to identify multiple sclerosis (MS) disease severity based on healthcare costs in a US administrative claims database (P20.052)","volume":"88","author":"Nicholas","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2025.106617_bib0011","first-page":"469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf","year":"2002","journal-title":"J. Manag. Care. Pharm."},{"issue":"2","key":"10.1016\/j.msard.2025.106617_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol. Open."},{"key":"10.1016\/j.msard.2025.106617_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102539","article-title":"Replication of a claims-based algorithm to estimate multiple sclerosis disease severity in a commercially insured population","volume":"46","author":"Toliver","year":"2020","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:21:39Z","timestamp":1780039299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":12,"alternative-id":["S2211034825003591"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106617","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world change in annualized relapse rate and healthcare resource utilization following initiation of ofatumumab in people with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106617"}}